Trans Genic Inc. (2342.T)
JPY 189.0
(2.72%)
JPY 189.0
(2.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.15 Billion JPY | 6.92% |
| 2022 | 2.01 Billion JPY | 1.07% |
| 2021 | 1.99 Billion JPY | 6.09% |
| 2020 | 1.88 Billion JPY | -5.8% |
| 2019 | 2 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 604 Million JPY | 10.11% |
| 2023 Q2 | 544.14 Million JPY | 2.21% |
| 2023 FY | 2.15 Billion JPY | 6.92% |
| 2023 Q3 | 534.72 Million JPY | -1.73% |
| 2023 Q1 | 532.4 Million JPY | -0.59% |
| 2023 Q4 | 548.54 Million JPY | 2.58% |
| 2022 Q3 | 507.69 Million JPY | 0.39% |
| 2022 FY | 2.01 Billion JPY | 1.07% |
| 2022 Q4 | 535.56 Million JPY | 5.49% |
| 2022 Q2 | 505.7 Million JPY | 0.0% |
| 2021 FY | 1.99 Billion JPY | 6.09% |
| 2020 FY | 1.88 Billion JPY | -5.8% |
| 2019 FY | 2 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -68.149% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -274.44% |
| GNI Group Ltd. | 9.32 Billion JPY | 76.832% |
| Linical Co., Ltd. | 2.7 Billion JPY | 20.16% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -44.842% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 29.672% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -16.309% |
| AnGes, Inc. | 8.9 Billion JPY | 75.738% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -129.018% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 88.745% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -422.973% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -121.436% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 15.881% |
| CanBas Co., Ltd. | 278 Million JPY | -676.916% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -89.204% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -18.806% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -34.672% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 9.024% |
| PeptiDream Inc. | 9.68 Billion JPY | 77.704% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -10.162% |
| Ribomic Inc. | 1.1 Billion JPY | -95.337% |
| SanBio Company Limited | 4.53 Billion JPY | 52.416% |
| Healios K.K. | 3.48 Billion JPY | 38.061% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -87.04% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -61.85% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -53.893% |
| StemRIM | 2.07 Billion JPY | -4.038% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -9.999% |
| FunPep Company Limited | 313.82 Million JPY | -588.235% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -125.449% |
| Stella Pharma Corporation | 963.98 Million JPY | -124.052% |
| TMS Co., Ltd. | 943.25 Million JPY | -128.976% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -98.158% |
| Cuorips Inc. | 598.11 Million JPY | -261.104% |
| K Pharma,Inc. | 543.94 Million JPY | -297.069% |
| Takara Bio Inc. | 23.9 Billion JPY | 90.965% |
| ReproCELL Incorporated | 1.51 Billion JPY | -42.656% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -82.419% |
| StemCell Institute Inc. | 1.16 Billion JPY | -85.852% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -41.881% |
| CellSeed Inc. | 804.93 Million JPY | -168.324% |